title: Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.
abstract: OBJECTIVE
  To investigate the protective effect of lansoprazole on ischemia and reperfusion (I/R)-induced rat intestinal mucosal injury in vivo.
  
  
  METHODS
  Intestinal damage was induced by clamping both the superior mesenteric artery and the celiac trunk for 30 min followed by reperfusion in male Sprague-Dawley rats. Lansoprazole was given to rats intraperitoneally 1 h before vascular clamping.
  
  
  RESULTS
  Both the intraluminal hemoglobin and protein levels, as indices of mucosal damage, significantly increased in I/R-groups comparison with those of sham-operation groups. These increases in intraluminal hemoglobin and protein levels were significantly inhibited by the treatment with lansoprazole at a dose of 1 mg/kg. Small intestine exposed to I/R resulted in mucosal inflammation that was characterized by significant increases in thiobarbituric acid-reactive substances (TBARS), tissue-associated myeloperoxidase activity (MPO), and mucosal content of rat cytokine-induced neutrophil chemoattractant-1 (CINC-1). These increases in TBARS, MPO activities and CINC-1 content in the intestinal mucosa after I/R were all inhibited by pretreatment with lansoprazole at a dose of 1 mg/kg. Furthermore, the CINC-1 mRNA expression was increased during intestinal I/R, and this increase in mRNA expression was inhibited by treatment with lansoprazole.
  
  
  CONCLUSIONS
  Lansoprazole inhibits lipid peroxidation and reduces development of intestinal mucosal inflammation induced by I/R in rats, suggesting that lansoprazole may have a therapeutic potential for I/R injury.
authors.affiliation: Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ichikawa
authors.forename: Norimasa
authors.initials: N
authors.lastname: Yoshida
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Takagi
authors.forename: Naoya
authors.initials: N
authors.lastname: Tomatsuri
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Katada
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Isozaki
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Yuji
authors.initials: Y
authors.lastname: Naito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000517:prevention & control; D007413:Intestinal Mucosa / Q000098:blood supply / Q000187:drug effects / Q000473:pathology*; D007511:Ischemia / Q000517:prevention & control*; D064747:Lansoprazole; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D005765:Gastrointestinal Agents; D064747:Lansoprazole; D009853:Omeprazole